Melissa Haendel, PhD, FACMI, was consulted for an article in E+ELeader on the “promise and risks” of artificial intelligence (AI) in North Carolina. In the article, Haendel points out that AI may be able to “help advance clinical trials of new drugs that are often slowed down or delayed by the failure to recruit and enroll enough patients.”
Read the full article on the E+ELeader website here: https://environmentenergyleader.com/premium/stories/ais-promise-and-risks-converge-in-north-carolina,122603